

Baseline Data

The following table shows the ocular baseline data which has been summarised on the eye-level.

Table 1: Ocular baseline data – eye level

	Adalimumab (n=77)	Placebo (n=38)	Total (n=115)
Topical steroid drops score ¹			
Mean (SD)	2.04 (1.38)	2.20 (1.57)	2.09 (1.44)
LogMAR score ²			
Mean (SD)	0.04 (0.15)	0.07 (0.12)	0.05 (0.14)
AC cells (SUN)			
1+	52 (68%)	24 (63%)	76 (66%)
2+	18 (23%)	11 (29%)	29 (25%)
3+	6 (8%)	3 (8%)	9 (8%)
4+	1 (1%)	0 (0%)	1 (1%)
Flare score (SUN)			
0	18 (23%)	12 (32%)	30 (26%)
1+	49 (64%)	23 (61%)	72 (63%)
2+	10 (13%)	3 (8%)	13 (11%)
LOCS III Grading: Pseudophakic			
No	77 (100%)	38 (100%)	115 (100%)
LOCS III Grading: Nuclear ³			
NO	69 (96%)	36 (97%)	105 (96%)
NI	3 (4%)	1 (3%)	4 (4%)
LOCS III Grading: Cortical ⁴			
No Cortical Cataract	56 (88%)	29 (94%)	85 (90%)
Ctr	3 (5%)	0 (0%)	3 (3%)
CI	4 (6%)	2 (7%)	6 (6%)
CII	1 (%)	0 (0%)	1 (1%)
LOCS III Grading: Posterior ⁵			
0	68 (92%)	29 (81%)	97 (88%)
PI	5 (7%)	4 (11%)	9 (8%)
PII	1 (1%)	3 (8%)	4 (4%)
Other Structural Changes: Central band-keratopathy – covering visual axis			
No	75 (97%)	38 (100%)	113 (98%)
Yes	2 (3%)	0 (0%)	2 (2%)
Other Structural Changes: Synchiae			
No	59 (77%)	32 (84%)	91 (79%)
Yes	18 (23%)	6 (16%)	24 (21%)
Other Structural Changes: Iris bombe			
No	77 (100%)	38 (100%)	115 (100%)
Other Structural Changes: Membrane formation			
No	75 (97%)	38 (100%)	113 (98%)

EudraCT Supplementary Material: Ocular Baseline Data

	Adalimumab (n=77)	Placebo (n=38)	Total (n=115)
Yes	2 (3%)	0 (0%)	2 (2%)
Other Structural Changes: Neovascularisation			
No	77 (100%)	38 (100%)	115 (100%)
IOP (mmHg)			
Mean (SD)	14.76 (3.85)	14.11 (4.27)	14.54 (3.99)
Vitreous Haze Grading			
0	65 (84%)	32 (84%)	97 (84%)
0.5+	8 (10%)	4 (11%)	12 (10%)
1+	3 (4%)	2 (5%)	5 (4%)
2+	1 (%)	0 (0%)	1 (1%)

1: 2 adalimumab, 3 placebo unobtainable; 2: 1 adalimumab unobtainable; 3: 5 adalimumab, 1 placebo unobtainable; 4: 13 adalimumab, 7 placebo unobtainable; 5: 3 adalimumab, 2 placebo unobtainable.